- Reaction score
- 747
Well on a happier note has anyone noticed the rise of Replicel's share price lately. Sounds like they are moving forward with their male pattern baldness injector:some are lol
message from the CEO
"In 2012, when we announced the safety and 6-month clinical efficacy data from our phase 1 study of RCH-01 (pattern baldness), we knew that in 2017 we would have 5-year safety data and both 12 and 24-month efficacy data which was all locked until the completion of the 5-year trial (all the trial participant data needed for this announcement has been collected and is now being prepared for third-party analysis)
While the dermal injector (RCI-02) program was almost completely static over 2016 given our lack of funds, we have now re-activated and prioritized the project to complete manufacturing of functional and tested prototypes in 2017 sufficient to support our filing of the CE mark application required to sell the device in Europe with label approval for injection of hyaluronic acid-based dermal fillers
http://www.stockhouse.com/news/press-releases/2017/01/05/replicel-ceo-provides-2017-forecast